QIAGEN Launches Human Druggable Genome siRNA Set V 2.0
A Powerful Tool for Drug Discovery using RNAi
VENLO, The Netherlands, October 5, 2005 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), the world ' s leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins today announced the first delivery of its new Human Druggable Genome siRNA Set V2.0 to the Scripps Research Institute in Florida. This second generation siRNA set from QIAGEN enables highly efficient and effective gene silencing studies of 6992 potential human druggable targets. siRNAs are designed using the innovative HiPerformance siRNA Design Algorithm, ensuring maximum silencing and minimum risk of non-specific effects.
"We selected the siRNA set from QIAGEN based on our criteria for siRNA design specificity, expertise in high throughput siRNA synthesis, and dedicated support," Dr. John Hogenesch , Director of Genome Technology said. "Biology in the post-genomic era is marked by the desire to study cells, cellular processes, and disease at a genome-wide level. The Genome Technology group at Scripps Florida aims to leverage these high-throughput tools and technologies toward a systematic description of genes encoded by the human genome, and a more comprehensive understanding of the genetic basis for human disease." Scripps Florida researchers will use the siRNAs in combination with an assortment of high-throughput phenotypic screening technologies to interrogate novel mammalian gene function in cell based assays.
"We are delighted that the Scripps research Institute selected the QIAGEN Human Druggable Genome siRNA Set", commented Dr. Jie Kang, VP R&D at QIAGEN. "Scripps joins a long list of other pharmaceutical, biotech and academic research centers in relying on QIAGEN's products and dedicated support for their high throughput RNAi applications. We look forward to contributing to more exciting discoveries and publications."
For more information, visit www.qiagen.com/siRNA.
About The Scripps Research Institute
The Scripps Research Institute, headquartered in La Jolla , California , in 15 buildings on 22 acres overlooking the Pacific Ocean , is one of the world's largest independent, non-profit biomedical research organizations. It stands at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its research into immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. Established in its current configuration in 1961, it employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel.
Scripps Florida , a 364,000 square-foot, state-of-the-art biomedical research facility, is under construction in Palm Beach County . The facility will focus on basic biomedical science, drug discovery, and the application of the latest research technologies. Palm Beach County and the State of Florida have provided start-up economic packages for development, building, staffing, and equipping the campus. Scripps Florida now operates with approximately 150 scientists, technicians, and administrative staff at 40,000 square-foot lab facilities on the Florida Atlantic University campus in Jupiter.
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, China, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,500 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with obtaining government approval of the proposed acquisition, management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products ( including fluctuations due to the level and timing of customers' funding, budgets, and other factors ), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
IR QIAGEN N.V.
Phone: +49 2103 29 11710
Fax: +49 2103 29 21710